Provided is a biodegradable ocular implant for sustained drug delivery, including a first layer comprising a first biodegradable polymer, wherein the first layer contains a drug dispersed or dissolved therein. A multi-layered biodegradable ocular implant is also disclosed.

The manufacturing method of the sheet having the needle-like protruding portions includes: preparing a mold including needle-like recessed portions, and a solution supply device including a slit-like opening formed at a nozzle distal end portion; supplying a solution from the solution supply device to the mold in a state that the nozzle distal end portion is pressed to a front surface of the mold, and filling the solution in the needle-like recessed portions; and moving the solution supply device relatively to the mold in a state that the nozzle distal end portion is brought into contact with the front surface of the mold, and, as a hardness distribution in a thickness direction of the mold, an average value of a Young's modulus at a part within 40 μm from the front surface of the mold is 1.9 MPa or higher and 100 MPa or lower.

A bioabsorbable composite stent structure, comprising bioabsorbable polymeric ring structures which retain a molecular weight and mechanical strength of a starting substrate and one or more interconnecting struts which extend between and couple adjacent ring structures. The ring structures can have a formed first diameter and being radially compressible to a smaller second diameter and re-expandable to the first diameter. The ring structures can comprise a base polymeric layer. The interconnecting struts can be formed from a polymer blend or co-polymer of poly-L-lactide (PLLA) and an elastomeric polymer. The interconnecting struts each can have a width that is less than a circumference of one of the ring structures. The adjacent ring structures can be axially and rotationally movable relative to one another via the interconnecting struts. The interconnecting struts can also be bioabsorbable.

Pharmacologically active implants, in particular subcutaneous implants, intrauterine devices, and intravaginal rings, are provided herein. Methods for forming an active ingredient-containing core are described. Methods for laminating an active ingredient-containing core to form a rate-controlling sheath are also described.

A device for occluding a vasculature of a patient including a micrograft having an absorbent polymeric structure with a lumen of transporting blood. The micrograft has a series of peaks and valleys formed by crimping. The occluding device is sufficiently small and flexible to be tracked on a guidewire and/or pushed through a microcatheter to a site within the vasculature of the patient. Delivery systems for delivering the micrografts are also disclosed.

A bioresorbable, implantable device having controlled drug delivery is disclosed herein. The bioresorbable, implantable device is configured as a film, a roll, a tube, and a stent. The bioresorbable, implantable device is configured to release an active ingredient (the “drug”) from the bioresorbable, implantable device when the bioresorbable, implantable device is implanted within a body. The bioresorbable, implantable device is configured to control the onset of the release of the drug, the sequence of drug delivery, and the duration of drug delivery by embedding the drug within at least one therapeutic layer positioned within bioresorbable, implantable device.

A microneedle chip and manufacturing method. The method comprises injecting, into a female mold, a fluid needle liquid, wherein forming cavities matching the shapes of needles of a microneedle chip are provided at the female mold and form a cavity array, injection inlets are provided at a surface of one side of the female mold, and air ejection openings are provided at a surface of another side of the female mold to form an air ejection surface; covering the air ejection surface of the female mold using a breathable film, and during injection, passing a gas through the breathable film so as to retain the liquid inside the forming cavities; curing the fluid needle liquid to form the microneedle chip, and demolding to obtain the same. By employing the air ejection openings and the breathable film, a liquid is retained while ejecting a gas, providing a favorable micro-injection effect.

Provided is a method of manufacturing a microneedle array in which an active ingredient is concentrated at a tip while an active ingredient content is guaranteed. In order to achieve the object, a method of manufacturing a microneedle array in which needle-like recessed portions of a mold are filled with a liquid to form one dose of a patch includes determining a filling amount of the liquid from a difference in mass of the mold before and after filling of the liquid, determining a filling state of the liquid in the mold filled with the liquid, sucking the mold in which the filling amount and the filling state of the liquid are determined to be normal from a rear face, and evaporating and drying a solvent of the liquid of the sucked mold.

The present invention is based on the identification of a cohort of polyurethane block copolymers that are particularly suited for use in pharmaceutical polymeric drug-device units and which offer improved control of drug release. In particular, there is provided a polymeric drug-device unit comprising a polyurethane block copolymer obtainable by reacting together a poly(alkylene oxide); a difunctional compound; a difunctional isocyanate; and optionally a block copolymer comprising poly(alkylene oxide) blocks; and quinagolide as a pharmaceutically active agent. The drug-device units may find application in the treatment and/or prevention of endometriosis.

The present invention is directed to a process for the preparation of a coated solid pharmaceutical dosage form using 3D printing technology.